Valuation

CRSPCRISPR Therapeutics AG

StockNasdaqSwitzerlandHealth careEU retail investors: available

−6.8% today · −18.3% over a year

1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 7% of the instruments we score

Quality, Stability: among the weakest; priced higher than most peers. No dividend.

CRISPR Therapeutics AG (CRSP) valuation against sector peers: P/B 2.5, free-cash-flow yield −9.1%, P/S 164.2.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricCRSPSector medianvs median
P/E—25.5 · n=26—
P/B2.53.6 · n=4530% below
P/S164.24.7 · n=403,407% above
EV/EBIT—22.4 · n=28—
Free-cash-flow yield−9.1%3.8% · n=39339% below
Dividend yield0.00%0.19% · n=99100% below
Return on equity−25.6%5.2% · n=56591% below
Return on invested capital−26.1%6.5% · n=47502% below
Gross margin—70.2% · n=39—
Net debt / EBITDA—2.08 · n=25—

Value factor: 6 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

NOVNNovartis AG22.06.718.45.7%2.8%10/10
NVSNovartis AG21.96.618.35.8%2.5%10/10
AZNAstraZeneca plc28.05.922.64.1%1.7%6/10
AZNAstraZeneca PLC28.05.922.54.1%1.2%6/10
NVONovo Nordisk A/S11.96.310.44.8%4.6%7/10
SANSanofi SA13.71.518.66.7%4.7%9/10
SNYSanofi13.71.518.56.8%4.3%7/10
GSKGSK plc14.45.011.77.8%3.6%9/10
TEVATeva Pharmaceutical Industries Limited100.76.444.32.4%0.0%5/10
ALCAlcon AG35.91.628.24.9%0.5%4/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 02 Nov 2026